Developed by Samsung Bioepis Co., Ltd., and commercialized by Sandoz, Pyzchiva® has been approved by the US Food and Drug Administration (FDA) for the treatment of certain chronic inflammatory ...
Sandoz initiated a transformation program to make its organization more agile, simpler and more efficient. The Company anticipates further major biosimilar launches in 2025, including Pyzchiva ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results